NCT00193193已完成2 期
A Randomized, Phase II Trial of Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin Administered Either Weekly or Every Four Weeks in the Treatment of Hormone Refractory Prostate Carcinoma
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 100
- 主要终点
- Overall response rate
研究概览
简要总结
In this trial we will investigate how this three-drug regimen may be improved, both with respect to efficacy and toxicity, by making some modifications in the dosing and schedule in the treatment of patients with hormone refractory prostate cancer.
详细描述
Upon determination of eligibility, patients will receive:
Paclitaxel + Estramustine + Carboplatin
Patients will receive weekly paclitaxel and low-dose estramustine, in combination with carboplatin administered either weekly r every four weeks.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Adenocarcinoma of the prostate not curable with local treatment
- •Disease progression while receiving hormonal therapy
- •Measurable or evaluable disease
- •Previous treatment with a maximum of one prior chemotherapy regimen
- •ECOG performance status 0, 1, or
- •Adequate bone marrow, liver and kidney function
- •Able to comprehend the nature of this study and give written informed consent
排除标准
- •You cannot participate in this study if any of the following apply to you:
- •Age < 18 years
- •History of treatment for an invasive malignancy within five years
- •Significant heart disease
- •Please note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
结局指标
主要结局
Overall response rate
次要结局
- Toxicity
- Overall survival
研究者
相似试验
已完成
2 期
Paclitaxel With or Without Viral Therapy in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal CancerRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaNCT01199263National Cancer Institute (NCI)108
已完成
2 期
Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast CancerTubular Breast CancerMucinous Breast CancerInvasive Ductal Breast CancerInflammatory Breast CancerNCT02199418RenJi Hospital132
终止
2 期
An Efficacy and Safety Study of MORAb-003 in Platinum-Resistant or Refractory Relapsed Ovarian CancerOvarian CancerNCT00738699Morphotek415
终止
2 期
Feasibility Study of Metronomic Chemotherapy for Locally Advanced HER2-Negative Breast CancerLocally Advanced HER2-negative Breast CancerNCT01329627Instituto do Cancer do Estado de São Paulo12
撤回
1 期
Reirradiation With Concurrent Paclitaxel for Breast CancerBreast CancerNCT02058667University of Kentucky